Q-omics provides the consensus-scored GAL3ST2 profile across patient tissues and cancer cell-line models. GAL3ST2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GAL3ST2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GAL3ST2 RNA expression shows 16,455 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where GAL3ST2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAL3ST2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAL3ST2 survival associations across molecular data types. GAL3ST2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAL3ST2 RNA expression–survival associations across cancer types. High GAL3ST2 expression shows unfavorable associations in KIRP, KIRC, ACC, CHOL and LUAD, but favorable associations in COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GAL3ST2 RNA expression.
This table summarizes GAL3ST2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GAL3ST2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAL3ST2 shows lower tumor expression in KIRC, KICH and COAD and higher tumor expression in STAD, BRCA and LUAD. The KIRC box plot shows higher GAL3ST2 RNA expression in normal versus tumor tissue (log2 FC = −0.320, t-test p < 0.001).
This table shows molecular features associated with GAL3ST2 in patient tissues and cancer cell lines. In patient samples, GAL3ST2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GAL3ST2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
